Analysts Offer Insights on Healthcare Companies: Paratek Pharmaceuticals (NASDAQ: PRTK) and Acer Therapeutics Inc (NASDAQ: ACER)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Paratek Pharmaceuticals (PRTKResearch Report) and Acer Therapeutics Inc (ACERResearch Report) with bullish sentiments.

Paratek Pharmaceuticals (PRTK)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Paratek Pharmaceuticals, with a price target of $27. The company’s shares closed yesterday at $3.76, close to its 52-week low of $3.40.

Arce said:

“We view the promotion of Dr. Loh as particularly well-deserved and quite likely to be broadly well-received by investors and other constituents. Affirm Buy.”

According to TipRanks.com, Arce is a 4-star analyst with an average return of 7.3% and a 36.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.

Currently, the analyst consensus on Paratek Pharmaceuticals is a Strong Buy with an average price target of $19.

See today’s analyst top recommended stocks >>

Acer Therapeutics Inc (ACER)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Acer Therapeutics Inc, with a price target of $10. The company’s shares closed yesterday at $4.12, close to its 52-week low of $3.83.

Selvaraju noted:

“Valuation methodology and risks. We value Acer using a composite risk-adjusted net present value (rNPV) approach, which employs a 15% discount rate and 30% tax rate, while ascribing a 60% and 50% probability of success to ACER-001 in MSUD and UCDs, respectively. This yields a total rNPV of $170M.”

According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.0% and a 30.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Acer Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $20.75, which is a 403.6% upside from current levels. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $8 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.